Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cervical cancer through a tissue biopsy, and whose cancer is planned to be treated with a combination of radiation and chemotherapy (rather than surgery as the main treatment)
- People whose cancer falls within a specific stage range (FIGO stages IB1 to IVa — confirm with trial site for what this means for a specific case)
- People who are over 18 years of age
- People who speak and understand Norwegian or English
- People whose general physical fitness level is rated as reasonably good (ECOG score of 0–2 — confirm with trial site)
- People whose cancer is one of these specific types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- People who are able to understand and complete patient questionnaires, and who are willing to sign a consent form
- People whose uterus moves by a certain amount during body functions — specifically, movement of 2.5 cm or more (confirm with trial site)
Who may not be able to join:
- People whose cancer has spread to distant parts of the body (though certain affected lymph nodes near the lower back may still be acceptable if they fall within the radiation treatment area — confirm with trial site)
- People who have already had surgery to treat their cervical cancer
- People with a serious ongoing physical illness that is not currently under control
- People with a psychiatric illness or personal circumstances that would make it difficult to follow the study requirements
- People who have previously had radiation therapy to the pelvic area
- People who are currently pregnant or breastfeeding, due to known risks associated with radiation therapy and the chemotherapy drug used in this trial
- People currently receiving treatment for another type of invasive cancer (skin cancers that are not melanoma are excepted)
- People who have a nephrostomy (a tube draining the kidney through the skin — confirm with trial site)
- People who have inflammatory bowel disease (a chronic condition affecting the digestive tract, such as Crohn's disease or ulcerative colitis)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kjersti Bruheim, MD PhD, Oslo University Hospital
Phone: +4723934000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To investigate whether implementation of the plan of the day concept results in less gastro-intestinal toxicity.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.